Effective Treatment for Uncomplicated Urinary Tract Infections with Oral Fosfomycin, Single Center Four Year Retrospective Study

被引:14
作者
Fajfr, Miroslav [1 ,2 ]
Balik, Michal [2 ,3 ]
Cermakova, Eva [4 ]
Bostik, Pavel [1 ,2 ,5 ]
机构
[1] Univ Hosp, Inst Clin Microbiol, Sokolska 581, Hradec Kralove 50005, Czech Republic
[2] Charles Univ Prague, Fac Med Hradec Kralove, Simkova 870, Hradec Kralove 50038, Czech Republic
[3] Univ Hosp, Dept Urol, Sokolska 581, Hradec Kralove 50005, Czech Republic
[4] Charles Univ Prague, Dept Med Biophys, Fac Med Hradec Kralove, Simkova 870, Hradec Kralove 50038, Czech Republic
[5] Univ Def, Fac Mil Hlth Sci, Trebesska 1575, Hradec Kralove 50001, Czech Republic
来源
ANTIBIOTICS-BASEL | 2020年 / 9卷 / 08期
关键词
fosfomycin; urinary infection; resistance; MULTIDRUG-RESISTANT; ENTEROBACTERIACEAE; SUSCEPTIBILITY; COMMUNITY;
D O I
10.3390/antibiotics9080511
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Fosfomycin represents a relatively old antibiotic, but it is experiencing a comeback in recent years. According to some studies, the increasing therapeutic use of this drug led to a rapid increase in the levels of resistance in bacteria causing urinary tract infection. In the presented study, levels of resistance to fosfomycin in more than 3500 bacterial isolates before and after fosfomycin introduction into therapeutic use in the Czech Republic and the clinical efficacy of treatment in 300 patients using this drug were assessed. The results show that the resistance levels to fosfomycin inEscherichia coliisolates before and after the drug registration were not significantly different (3.4% and 4.4%, respectively). In some other Gram-negative rods, such as otherwise susceptibleEnterobacter, resistance to fosfomycin increased significantly from 45.6% to 76.6%. Fosfomycin treatment of urinary tract infections showed an excellent seven-day clinical efficacy (79.7%). However, when used to treat recurrent or complicated urinary tract infections, fosfomycin treatment was associated with high levels of infection relapse, leading to relapse in a total of 20.4% of patients during the first two months. This indicates that fosfomycin exhibits good efficacy only for the treatment of uncomplicated urinary tract infections
引用
收藏
页码:1 / 9
页数:9
相关论文
共 27 条
[1]   Fosfomycin: mechanisms and the increasing prevalence of resistance [J].
Aghamali, Mina ;
Sedighi, Mansour ;
Bialvaei, Abed Zahedi ;
Mohammadzadeh, Nima ;
Abbasian, Sara ;
Ghafouri, Zahra ;
Kouhsari, Ebrahim .
JOURNAL OF MEDICAL MICROBIOLOGY, 2019, 68 (01) :11-25
[2]   The Activity of Fosfomycin Against Extended-Spectrum Beta-Lactamase-Producing Isolates of Enterobacteriaceae Recovered from Urinary Tract Infections: A Single-Center Study Over a Period of 12 Years [J].
Aris, Parisa ;
Boroumand, Mohammad Ali ;
Rahbar, Mohammad ;
Douraghi, Masoumeh .
MICROBIAL DRUG RESISTANCE, 2018, 24 (05) :607-612
[3]   An update on the management of urinary tract infections in the era of antimicrobial resistance [J].
Bader, Mazen S. ;
Loeb, Mark ;
Brooks, Annie A. .
POSTGRADUATE MEDICINE, 2017, 129 (02) :242-258
[4]   Evaluation of the in vitro activity of fosfomycin tromethamine against Gram-negative bacterial strains recovered from community- and hospital-acquired urinary tract infections in Turkey [J].
Demir, Tulin ;
Buyukguclu, Tuncay .
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2013, 17 (11) :E966-E970
[5]  
Díez-Aguilar M, 2019, REV ESP QUIM, V32, P8
[6]   The susceptibility to fosfomycin of Gram-negative bacteria isolates from urinary tract infection in the Czech Republic: data from a unicentric study [J].
Fajfr, Miroslav ;
Louda, Miroslav ;
Paterova, Pavla ;
Ryskova, Lenka ;
Pacovsky, Jaroslav ;
Kosina, Josef ;
Zemlickova, Helena ;
Brodak, Milos .
BMC UROLOGY, 2017, 17
[7]   Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum β-lactamase producing, Enterobacteriaceae infections: a systematic review [J].
Falagas, Matthew E. ;
Kastoris, Antonia C. ;
Kapaskelis, Anastasios M. ;
Karageorgopoulos, Drosos E. .
LANCET INFECTIOUS DISEASES, 2010, 10 (01) :43-50
[8]  
Frimondt-MOller N., 2010, KUCERS USE ANTIBIOTI, V6th
[9]  
Gajdacs M, 2019, ANTIBIOTICS BASEL, V8
[10]   Resistance Trends and Epidemiology of Citrobacter-Enterobacter-Serratia in Urinary Tract Infections of Inpatients and Outpatients (RECESUTI): A 10-Year Survey [J].
Gajdacs, Mario ;
Urban, Edit .
MEDICINA-LITHUANIA, 2019, 55 (06)